ArticleBMC infectious diseases2025
Oritavancin in LVAD related infections - a chance for shortening therapy and improving outcomes.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLVAD utility in heart failure patients is growing. Despite advancement in technology rates of LVAD- related infections remain high limiting outcomes. We aimed to assess the effectiveness and safety of oritavancin for LVAD-related Gram-positive infections.
methodsA retrospective study evaluating adult LVAD patients who received ≥ 1 oritavancin dose for treatment of Gram-positive LVAD-related infection between September 2022 and December 2024. Oritavancin was given at the end of shortened standard antibiotic therapy. The primary endpoint was 90-day clinical and microbiological cure of the primary or relapsing infection within 90 days from the first oritavancin dose. Secondary endpoints were adverse events.
resultsOverall, nine patients were included. All were male, mean age was 53 ± 9 years. In total they experienced 10 LVAD- related episodes. Most episodes (80%) were deep drive-line infections. The organism most commonly responsible for infection was Staphyloccocus aureus. Oritavancin was administered after a median time of 31 ± 13 days of standard antibiotic therapy. In total 18 doses of oritavancin were administered with a median of 2 per case separated on average by 20 ± 4 days. Primary endpoint was achieved in 90% of cases, shortening therapy by a median time of 24 days. Serious adverse events occurred in two of 9 patients: delirium and shivers, both with transient increase of inflammatory markers.
conclusionOritavancin has a potential to shorten inhospital therapy and improve outcomes in LVAD-related Gram-positive infections in advanced heart failure patients. The study is the first to report delirium and transient increase in inflammatory biomarkes as side effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.